华仁药业(300110.SZ)发布2022年半年度业绩预告，预计上半年归属于上市公司股东的净利润6615.77万元至8085.94万元，比上年同期变动：-10%至10%。
受疫情和宏观环境影响，上半年能源、物流成本不断增加，压缩了公司的利润空间。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台用户上传并发布，不构成投资建议请自行甄别，如有侵权请联系删除：liaycn@163.com
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of the site, which is a social media platform and only provides information storage services.